



OPEN Facile preparation of silver based radiosensitizers via biomineralization method for enhanced in vivo breast cancer radiotherapy

Mohammadreza Ghaffarlou¹, Ali Mohammadi², Navid Mousazadeh², Marziyeh Salehiabar², Yahya Kalantari², Jalil Charmi², Murat Barsbay¹, Yavuz Nuri Ertas^{3,4}, Hossein Danafar², Hamed Rezaeejam⁵✉, Hamed Nosrati²✉ & Siamak Javani^{6,7}✉

To solve the traditional radiotherapy obstacles, and also to enhance the radiation therapy efficacy various radiosensitizers have been developed. Radiosensitizers are promising agents that under X-ray irradiation enhance injury to tumor tissue by accelerating DNA damage. In this report, silver-silver sulfide nanoparticles (Ag-Ag₂S NPs) were synthesized via a facile, one-pot and environmentally friendly biomineralization method. Ag-Ag₂S was coated with bovine serum albumin (BSA) in situ and applied as an X-ray sensitizer to enhance the efficiency of radiotherapy. Also, folic acid (FA) was conjugated to Ag-Ag₂S@BSA to impart active targeting capability to the final formulation (Ag-Ag₂S@BSA-FA). Prepared NPs were characterized by transmission electron microscopes (TEM), scanning electron microscope (SEM), dynamic light scattering (DLS), ultraviolet–visible spectroscopy (UV–Vis), X-ray diffraction analysis (XRD), and X-ray photoelectron spectroscopy (XPS) techniques. Results show that most of the NPs have well-defined uniform Janus structures. The biocompatibility of the NPs was then evaluated both in vitro and in vivo. A series of in vitro assays were performed on 4T1 cancer cells to evaluate the therapeutic efficacy of the designed NPs. In addition, the radio-enhancing ability of the NPs was tested on the 4T1 breast cancer murine model. MTT, live and dead cell staining, apoptosis, ROS generation, and clonogenic in vitro assays demonstrated the efficacy of NPs as radiosensitizers in radiotherapy. In vivo results as well as H&E staining tumor tissues confirmed tumor destruction in the group that received Ag-Ag₂S@BSA-FA NPs and exposed to X-ray. The results showed that prepared tumor-targeted Ag-Ag₂S@BSA-FA NPs could be potential candidates as radiosensitizers for enhanced radiotherapy.

Cancer is an uncontrolled process of abnormal cell growth that inhibits apoptosis messages in cells, causing serious disease and highly noticeable mortality, almost 10 million deaths worldwide in 2020. Breast cancer affects one out of four women and is the cause of one out of every six cancer deaths and ranks first in incidence in the majority of countries (159 out of 185)^{1–3}. Cancer has traditionally been treated with surgery and chemotherapy. Radiation therapy (RT) is a branch of oncology based on radiation therapy that can be used alone or in combination with surgery and chemotherapy to achieve local control of breast cancer. RT often uses high-energy radiation, such as X-rays or gamma rays to ionize atoms or molecules in order to directly or indirectly damage DNA blocks in cancer cells or to destroy the tumor, which is employed in at least 50% of all solid malignancies, and

¹Department of Chemistry, Hacettepe University, Beytepe, Ankara 06800, Turkey. ²Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran. ³ERNAM-Nanotechnology Research and Application Center, Erciyes University, Kayseri 38039, Turkey. ⁴Department of Biomedical Engineering, Erciyes University, Kayseri 38039, Turkey. ⁵Department of Radiology Technology, School of Allied Medical Sciences, Zanjan University of Medical Sciences, Zanjan 45139-56184, Iran. ⁶Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran. ⁷School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran. ✉email: hrezaeejam@yahoo.com; Nosrati.hamed2020@gmail.com; siamackjavani@yahoo.com

extends the life expectancy of cancer patients^{4,5}. Acute or late toxicity, such as edema, fibrosis, and telangiectasia, can be seen in normal tissue during radiation treatment, which poses significant barriers to increasing the radiation dose. Therefore, decreasing the dosage of RT may be an appropriate target to eradicate the aforementioned problems. To address this issue, different radiosensitizers have been introduced in the RT procedure with enormous potential in cancer therapy⁶. The radiosensitizing agents usually trigger tumor cells to be more sensitive to ionizing radiation by promoting the generation of free radicals and accelerating DNA damage. Recently, there has been rapid progress in the development of nanotechnology-based materials in combination with new medical technologies, which have provided promising and rational design in the development of radiation sensitizers with excellent physicochemical features such as intrinsic radiosensitivity, high drug loading capacity, capability of tumor-targeting by enhanced permeability retention (EPR) effect, appropriate biocompatibility and low toxicity to normal tissues^{7–9}. Nanotechnology and the use of nanoparticles (NPs) based on metal atoms with high atomic numbers in combination with radiation therapy to enhance the effect of radiation by accumulating more in the tumor area compared to healthy tissues can effectively increase the efficiency of radiation therapy and reduce side effects^{10,11}. NPs of high atomic number elements such as gold, bismuth, platinum, silver and some lanthanides can increase the effective dose of ionizing radiation in tumor tissue and consequently the therapeutic effect due to their high ionizing radiation absorption mechanism and emissions of secondary electrons with Compton scattering and photoelectric effect¹². The presence of NPs in cancer cells increases the production of ROS, which increases oxidative stress and the amount of effective radiation damage by restricting the cells in the radiation-sensitive phase (M, G2) and inhibiting DNA repair^{13–15}.

Silver NPs (AgNPs) are virtually non-toxic at low concentrations, but they can accumulate in mammalian cells and interact with intracellular components, causing side effects and infections in various organs. The properties of AgNPs strongly depend on their size, shape and crystallinity. Their large specific surface area and high surface energy lead AgNPs to self-aggregate, which significantly reduces their application. Silver NPs are used for multifunctional biomedical applications^{16,17}. It is beneficial to utilize different stabilizers to solve this limitation^{18,19}. Researchers have recently extensively used albumin protein to coat and stabilize various NPs such as gold, silver and iron oxide NPs^{20,21}. Bovine serum albumin (BSA) has found many applications in drug delivery due to its easy production and reasonable price, high drug loading capacity, convenient targeting, ligand binding and cell uptake capabilities, biocompatibility and biodegradability²². For instance, in 2013, US researchers designed BSA-coated AgNPs with an FCC crystal structure and an average size of 11–15 nm. They used BSA as an effective protective agent to prevent the accumulation of AgNPs. Thiol-containing cysteine residues bonded with AgNPs, possibly via direct chemical interactions, generating a stabilizing effect due to the presence of bulky protein molecules. The findings also showed that the composition and structure of AgNPs/BSA can have a major impact on the bioavailability, antimicrobial activity and overall behavior of protein-conjugated NPs in the biological system²¹. In addition, De-Hao et al. showed that the colloidal stability of BSA-conjugated AgNPs increase significantly compared to bare NPs over the pH range of 2.3–7²³. Peidang et al. also introduced AS1411 aptamer and verapamil conjugated BSA coated AgNPs (AgNPs@BSA-AS-VRP) as promising radiosensitizing and radioresistance agent for glioma radiotherapy. Their results yielded a sensitization enhancement ratio (SER) of 1.55, suggesting excellent potential for enhancing the efficacy of radiotherapy²⁴.

It is important to note that using Ag₂S with Ag NPs can generate NPs whose properties may be markedly different in comparison to Ag₂S and Ag NPs alone, due to the interactions resulting from small variations in electron transferring across the interface between these two limited electron 'nano-reservoirs'. Having excellent photoelectric and photocatalytic properties as well as chemical stability^{25,26} of Ag and Ag₂S nanomaterials, we decided to evaluate the properties of Ag-Ag₂S Janus NPs as radiosensitizers for radiotherapy (Fig. 1). This study aims to introduce novel Janus nanoradiosensitizers to improve the efficacy of in vitro and in vivo radiotherapy of breast cancer treatment by targeting the tumor via FA conjugated and BSA coated Ag-Ag₂S NPs to sensitize tumor cells to radiation-induced damage.

Materials and methods

All methods used in this study were conducted in accordance with relevant guidelines and regulations of the Ethics Committee of the Iran National Science Foundation (Code: INSF-98026551).

Materials. Silver nitrate (Ag(NO₃),5H₂O), bovine serum albumin (BSA), folic acid (FA), N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (NHS), dimethyl sulfoxide (DMSO) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, USA). Nitric acid (HNO₃), sodium hydroxide (NaOH) and ammonium hydroxide (NH₄OH) were purchased from Merck (Kenilworth, USA) and used without any further purification. All glassware and magnetic Teflon coated beads were cleaned in the aqua regia solution, then repeatedly washed with distilled water (DI) and dried in the oven. Other chemical materials were provided by a local market.

Methods. *Synthesis of silver-silver sulfide NPs coated with bovine serum albumin (Ag-Ag₂S@BSA).* 125 mg Ag(NO₃),5H₂O (2 mL) was slowly added to a 16 mL aqueous solution of BSA (31.25 mg/mL) under stirring. Then NaOH solution (1.5 M) was added to adjust pH to 12²⁷. The reaction was stirred at room temperature with a magnetic stirrer for 24 h. For purification, the reaction solution was dialyzed for 48 h, then stored at 4 °C. The general synthesis scheme of Ag-Ag₂S@BSA NPs is illustrated in Fig. 1.

Synthesis of FA conjugated Ag-Ag₂S@BSA (Ag-Ag₂S@BSA-FA). For binding FA to the surface of Ag-Ag₂S@BSA NPs, the carboxyl groups of FA were first activated by EDC/NHS. For this purpose, 31.6 mg of EDC, 20 mg of NHS and 15 mg of FA were dissolved in 2 mL of DMSO. The above solution was then added to an aqueous




Figure 1. Schematic illustration of the synthesis of Ag-Ag₂S@BSA NPs and Ag-Ag₂S@BSA-FA NPs, and their radiosensitizing function.

solution containing 150 mg of Ag-Ag₂S@BSA NPs. After adjusting the pH of the reaction solution to 8.2 with NaOH, the solution was stirred in a dark environment for 24 h. To remove unreacted FA and other reactants, the reaction solution was dialyzed. The general scheme of Ag-Ag₂S@BSA-FA synthesis is shown in Fig. 1.

Preparation of fluorescein isothiocyanate (FITC) labeled Ag-Ag₂S@BSA-FA. To covalently attach FITC moieties to the surface of the NPs through the reaction of isothiocyanate groups of FITC, a solution of Ag-Ag₂S@BSA or Ag-Ag₂S@BSA-FA was mixed with FITC solution in a 1:10 ratio and shaken at room temperature overnight, according to the method in the literature²⁸. Then, excess FITC was extracted from the solution by dialysis for 48 h. All steps were performed in dark environment.

Characterization. The crystalline structure was characterized by X-ray diffraction (XRD; a Bruker AXS model D8 Advance diffractometer) by using a Cu-Kα1 radiation source, $\lambda = 0.15406$ nm. The XRD data in 2 θ ranging from 10° to 80° were collected with a scanning step size of 0.02°. X-ray photoelectron spectroscopy (XPS) measurements were performed using a mono-chromatized Al K α X-ray source (Thermo Scientific). Morphologies and size of nanostructures were determined by transmission electron microscopy (TEM; FEI 120 kV), and scanning electron microscopy (SEM; Vega Tescan). Dynamic light scattering (DLS; Malvern Instruments, Worcestershire, UK, model Nano ZS) was used to determine the hydrodynamic size of NPs. NPs were dispersed in deionized H₂O and the size was measured by DLS (Malvern Instruments, Worcestershire, UK, model Nano ZS). Spectroscopic characterizations were carried out using ultraviolet–visible spectroscopy (UV–Vis; Thermo Fisher Scientific, USA, Madison, model GENESYS10S). For analyzing samples by UV–Vis, they were dispersed in deionized H₂O, and measured in the range of 600–200 nm.

Colloidal stability of Ag-Ag₂S@BSA NPs. To monitor the stability of NPs, it was dispersed in water and PBS, then the size of NPs was measured at different time intervals.

Determination of the amount of FA conjugation. 0.5 mg of Ag-Ag₂S@BSA-FA and proteinase K (1 mL, 65:35 PBS:Ethanol at pH 7) were mixed and shaken at 37 °C for 24 h. Following centrifugation at 18,000 rpm, the supernatant (released FA) was measured with a UV–Vis spectrophotometer at 352 nm to calculate the amount of conjugated FA.

Cytotoxicity study. To determine the biocompatibility of the prepared Ag-Ag₂S@BSA-FA, cell viability was evaluated on HFF-2 fibroblast cells by MTT assay. Briefly, HFF-2 cells in 100 µl complete culture medium were transferred to a 96-well plate and incubated at 37 °C with moisture containing 5% CO₂ for 24 h. The culture medium was considered as the control. The cells were then treated with Ag-Ag₂S@BSA-FA NPs at three concentrations (1.3, 4 and 12 µg/ml) for 5 h. The culture medium was drained and fresh culture medium was added to each well. In the next step, the cells were incubated for another 24 h. Then, 20 µl of MTT at a concentration of 5 mg/mL was added to each well and incubated for 4 h. Following removing the solution from each well, 100 µl of DMSO was added and then the absorbance of each well was measured at 570/630 nm with a microplate reader (Tecan).

Hemolysis. Since NPs encounter blood in the biological environment when injected intravenously, it is important to determine their blood compatibility. For this purpose, 500 µl of solution containing NPs in 3 different concentrations and human red blood cells were poured into Eppendorf and placed in a shaker (37 °C) for 4h. It is noteworthy that deionized water was considered as the positive control and PBS as the negative control. The samples were then centrifuged at 13,000 rpm for 15 min and finally the absorbance of the supernatant was measured at 540 nm. The amount of hemolysis was calculated using the following equation.

$$\% \text{ Hemolysis} = \frac{A(\text{sample}) - A(\text{negative})}{A(\text{positive}) - A(\text{negative})} \times 100$$

LD50 assay. The LD50 test was used to determine the toxicity of NPs upon injection into the Balb/C mice. Different doses of 0, 44.44, 66.66 and 100 mg/kg were intravenously injected into mice (N = 4) and survival of the mice was monitored for 30 days.

Cytotoxicity study on cancer cells. MTT assay was used to determine the radiosensitizing ability of NPs under X-ray irradiation. The mouse breast cancer cells (4T1) were co-incubated with different NP concentrations. After the 5h incubation period, the medium containing NPs were replaced with fresh culture medium. Following X-ray irradiation of cells at a dose of 4 Gy (6 MV) and incubation for a further 24 h, the above-mentioned MTT assay was performed to determine the cell viability of each group.

Cellular uptake and internalization efficacy. To determine the effect of the presence of FA moieties on the internalization of NPs into cells, the cellular uptake rate was evaluated by flow cytometry. First, 50,000 cells were placed in a 24-well plate mixed with 500 µl of culture medium, and after 24 h the cells were washed with PBS and co-incubated with FITC labeled NPs (Ag-Ag₂S@BSA-FITC and Ag-Ag₂S@BSA-FA-FITC) at concentrations of 1.3, 4 and 12 µg/mL. After 5 h, the samples were washed with PBS, then trypsinized and analyzed by flow cytometer (BD Biosciences, San Jose, CA).

Intracellular ROS generation. To determine the ability of designed NPs to produce ROS, the 4T1 cells were cultured in a 96-well plate with 5000 cells and incubated overnight. After incubation, cells were co-incubated with different treatment groups, including control, X-ray, Ag-Ag₂S@BSA-FA, Ag-Ag₂S@BSA + X-ray and Ag-Ag₂S@BSA-FA + X-ray, for 5 h. Then, cells were washed and incubated for 1 h in RPMI-1640 medium containing 20 µM 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA). In the next step, cell wells were irradiated (4 Gy, 6 MV) and observed by a fluorescence microscope.

Calcein AM/PI cell staining assay. Nanoradiosensitizer-triggered death of 4T1 cells upon X-ray irradiation was exploited via the Calcein AM/PI (propidium iodide) staining method. Briefly, 4T1 cells were seeded in a 96-well plate (5000 cells per well) and incubated for 24 h, followed by exposure to various treatment regimens, including control, X-ray, Ag-Ag₂S@BSA-FA, Ag-Ag₂S@BSA + X-ray and Ag-Ag₂S@BSA-FA + X-ray, they were incubated for another 24 h. Next, Calcein AM (3 µM) was added and the cells were incubated for 30 min followed by 5 min incubation with PI (4 µM). Eventually, green (live) and red (dead) fluorescence images of 4T1 cells were documented.

Clonogenic assay. 4T1 cells were seeded in a 6-well plate with complete medium cell culture and incubated for 24 h. The intended samples were then added to the wells, which were either exposed or not by X-ray. Then, the cells were incubated for an additional 7 days, fixed with methanol:acetic acid (3:1) and stained with crystal violet. Finally, the number of colonies was counted²⁹.

In vivo study. 10⁶ 4T1 cells were injected subcutaneously into the right flank of Balb/C mice in order to generate tumors. After the tumor volume reached 100 mm³, the mice were randomly divided into 5 groups (N = 5): PBS, PBS + 4 Gy X-Ray, Ag-Ag₂S@BSA + 4 Gy X-Ray, Ag-Ag₂S@BSA-FA and Ag-Ag₂S@BSA-FA + 4 Gy X-ray. For the treatment plan, targeted mice were exposed to X-Ray (4Gy, 6MV) 24 h after intravenous injection of NPs. They were returned to the animal chamber after irradiation to evaluate the treatment process, tumor size and weight of the mice. The following formula was used to calculate the relative tumor volume.

$$\text{Relative Tumor Volume} = \frac{(\text{Tumor length}) \times (\text{Tumor width})^2}{2}$$

Histology study. The tumors and key organs were harvested from mice in different groups and fixed in a 4% paraformaldehyde solution. The specimens were then sent to a histology laboratory for histopathological evaluation.

Statistical analysis. All of the quantitative data were expressed as the mean with standard deviation (mean \pm SD) unless otherwise stated. Statistical analysis was performed using GraphPad Prism 8 software.

Ethics approval and consent to participate. This study was approved by the Ethics Committee of the Iran National Science Foundation (Code: INSF-98026551). Experimental descriptions in this manuscript comply with the ARRIVE guidelines.

Results

Characterization. Here, we synthesized promising novel radiosensitizers based on Janus-type Ag-Ag₂S NPs for enhanced breast cancer treatment in a murine model. Ag-Ag₂S@BSA NPs were prepared by a well-documented biomineralization process in a basic media³⁰. It is well-known that BSA may be denatured to liberate several residues under strong basic conditions^{31,32}. Under high basic conditions, BSA may be denatured to release several residues. For example, cysteine is a great sulfur source for producing metal sulfide NPs^{27,33}. In this nature-inspired process, BSA acts both as a sulfur source for the preparation of Ag₂S and as a stabilizer and scaffold in the mineralization of Ag-Ag₂S nanocrystals, similar to the production of inorganic biomaterials through the regulation of biological macromolecules in living organisms. Following their synthesis and




Figure 2. (a) SEM; (b,c) TEM image and related size distribution of Ag-Ag₂S@BSA-FA (Insert image: TEM image of Ag-Ag₂S@BSA); (d) Hydrodynamic size of Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA; (e) TEM-EDS-mapping of Ag-Ag₂S@BSA-FA NPs; (f) UV-Vis spectra of Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA NPs; (g) X-ray diffraction pattern of Ag-Ag₂S@BSA NPs.

subsequent modifications with targeting agent, Ag-Ag₂S@BSA-FA NPs were characterized by several methods. As can be seen from the SEM image of Ag-Ag₂S@BSA-FA NPs taken from the powder sample (Fig. 2a), the NPs are obscured by BSA, but they are still almost completely spherical and can be seen individually. From the TEM image taken after the powder was dissolved in water (Fig. 2b), it can be seen that Ag-Ag₂S@BSA-FA NPs are well dispersed without aggregation, spherical with a size of approximately 20.60 ± 4.7 nm (n = 30), and have a uniform size distribution. As can obviously be seen in the inserted image of Fig. 2c small Ag NPs appear to be in close contact with Ag₂S spheres. As a result of different phase compositions and electron densities, different contrasts are seen in the TEM image, confirming the existence of two different NPs. Although there is no discernible interface, small Ag NPs appear to be in close contact with Ag₂S spheres, like a patch or a matrix (well-defined uniform Janus structures)²⁶.

From DLS analysis, Ag-Ag₂S@BSA NPs presented an average hydrodynamic diameter of 25 nm and a polydispersity index (PDI) of 0.457 (Fig. 2d). Size monitoring of NPs shows that, there was no significant size difference during one month (Fig. S1). After conjugation of FA to the construct, the size slightly increased to 66 nm, while PDI was found to be 0.474 for Ag-Ag₂S@BSA-FA (Fig. 2d). The DLS technique was also used to assess the surface charge of the final formulation. According to zeta potential measurements performed with DLS, the surface charge of Ag-Ag₂S@BSA-FA NPs was found to be -23.2 mV, which is quite promising for the reasons mentioned above. DLS result indicates that this system is suitable in size for biological studies, including in vivo assays. The surface charge of the particles is a parameter for the system's colloidal stability. Highly negatively or positively charged NPs tend to repel each other and do not tend to aggregate. NPs interact with or adhere to oppositely charged cell layers, therefore, surface charge is also important in the accumulation of NPs in the bloodstream. Plasma and blood cells (biological elements) have a negative charge. For this reason, negatively charged NPs cannot electrostatically bind to blood cells and thus have a high circulation time in the blood^{28,29}. Composition was also confirmed by TEM-EDS mapping which highlighted the presence of Ag, and S elements in the structure of hybrid (Fig. 2e).

A UV-Vis spectrophotometer was used to investigate the presence of the components of the Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA constructs. As shown in Fig. 2f, the broad peak around 400 nm in the spectra of Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA NPs suggests the presence of silver NPs. BSA absorbance was seen around 268 nm in both spectra. After folic acid binding to Ag-Ag₂S@BSA NPs, a new peak around 302 nm appeared, which matched well with FA. The appearance of peaks at 400 nm, 268 nm, and 302 nm corresponded to silver NPs, BSA coating and FA, respectively^{34,35}. The amount of FA bound to the surface of Ag-Ag₂S@BSA was measured at 352 nm after its release using proteinase K, resulting in a loading rate of ~8.2%.

The X-ray diffraction pattern of Ag-Ag₂S@BSA NPs in Fig. 2g presents a broad peak centered around 2θ of 20° corresponding to the BSA^{26,28}. The XRD peaks observed at 2θ of 38.2°, 44.3°, 64.7°, and 77.4° can be attributed to the (111), (200), (220) and (311) crystallographic planes of face-centered cubic silver nanocrystals, respectively, and match well with the JCPDS card, no. 65-8428 for silver NPs³⁶. In addition, slight peaks at 34.6° and 37.0° correspond to the (121) and (213) planes of Ag₂S NPs (JCPDS card, no. 65-2356), respectively^{26,37}. Thus, the XRD study confirmed the presence of silver and silver sulfide in Ag-Ag₂S@BSA and the absence of other obvious phases in the structure as impurities.

In order to further elucidate the structure of Ag-Ag₂S@BSA-FA NPs and to investigate the oxidation state of Ag we have carried out XPS analysis. The wide range XPS scan, depicting the strong existence of binding energies for C 1s, O 1s, N 1s, Ag 3d, and S 2p, is shown in Fig. 3a. The high C, O and N content in this spectrum, reaching 61.0%, 17.8% and 17.2%, respectively, indicates that the surface composition of the NPs to a depth of about 10 nm is largely dominated by BSA and FA. The N/O molar ratio detected by XPS is about 0.97. This ratio implies a higher nitrogen content in comparison to the chemical composition of BSA. This elevated nitrogen presence can be attributed to the integration of nitrogen-rich FA into the structural framework. The C1s core-level scan in Fig. 3b confirms the presence of BSA and FA by showing the characteristic C-C/C-H, C-O/C-N and C=O/O-C-O/N-C=O components consistent with their structures^{38,39}. The Ag 3d spectrum is characterized by the doublets arising from spin orbital separation, which correspond to the core levels of Ag 3d_{5/2} and Ag 3d_{3/2} at approximately 367.7 and 373.6 eV, respectively^{40,41}. The higher binding energy components can be assigned to zero-valent species of Ag NPs, while the peaks at about 367.4 eV and 373.3 eV may be attributed to Ag(I) ions in Ag₂S (Fig. 3c)⁴², in the structure of Ag-Ag₂S@BSA-FA NPs. The binding energies for Ag (0) and Ag (I) species overlap due to very similar peak positions. However, it is reported that Ag 3d photoelectrons shift




Figure 3. XPS analysis of Ag-Ag₂S@BSA-FA NPs: (a) Wide-scan survey spectrum, (b) High-resolution XPS spectrum of C 1s photoelectrons, and (c) High-resolution XPS spectrum of Ag 3d photoelectrons.

slightly to lower binding energies when Ag-S bond is formed^{19,43–45}. As can be seen in Fig. 3c, Ag 3d_{3/2} and Ag 3d_{5/2} core levels are clearly curve-fitted into two Ag and Ag₂S peak components, confirming the coexistence of both nanocrystals in Ag-Ag₂S@BSA-FA NPs.

In vitro assays. *Analysis of hemocompatibility.* To assess the blood compatibility of Ag-Ag₂S@BSA-FA NPs, hemolysis testing was performed at three concentrations (1.3, 4, and 12 µg/mL) as shown in Fig. 4a. Water was used as a positive control and PBS solution was employed as a negative control. As can be seen in Fig. 4a, the aforementioned samples have a lysis rate of less than 3% even at the highest concentration (12 µg/mL), which indicates an appropriate hemocompatibility. Materials with less than 5% hemolysis are considered non-hemolytic materials based on American Society for Testing and Materials (ASTM)^{46,47}.

Analysis of cytotoxicity against healthy cells. MTT assay was used to investigate the cytotoxicity of Ag-Ag₂S@BSA-FA NPs on healthy HFF2 cells. As shown in Fig. 4b, the results of the MTT assay showed that Ag-Ag₂S@BSA-FA NPs prepared at concentrations of 1.3, 4 and 12 µg/mL had no noticeable inhibitory effect on the treated cells, which means that the designed NPs were fortunately non-toxic to healthy cells.

Cellular uptake and internalization efficacy. As can be seen from Fig. 4c, the cellular uptake results of NPs by the mouse breast cancer cells (4T1) showed a concentration-dependent cell internalization. Moreover, FA-conjugated NPs exhibited a higher uptake rate at all studied concentrations compared to Ag-Ag₂S@BSA NPs. Due to the overexpression of folate receptors on cancer cells, FA-conjugated NPs are more likely to be internalized by them⁴⁸.

In vitro antitumor activity. The MTT assay was used to determine the toxicity of Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA NPs on the mouse breast cancer cell line (4T1) at three concentrations of 1.3 µg/mL, 4 µg/mL, and 12 µg/mL, in the presence and absence of X-ray radiation. As shown in Fig. 4d, the NPs-free group (containing culture medium only) has 100% viability. As shown in anticancer study result, the therapeutic effect increased with increasing concentrations of NPs. The cell group irradiated by 4Gy dose showed 85% viability. The cell survival rate of the group treated with Ag-Ag₂S@BSA NPs (1.3 µg/mL) in the presence of irradiation was approximately 77%. The viability of cells co-treated with NPs (12 µg/mL) and X-ray irradiation decreased to 61% and 58% in the presence of Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA NPs, respectively. These results proved that the prepared NPs exhibited a better therapeutic effect compared to the group that received only X-Ray radiation, suggesting enhanced radiosensitivity in the case of the NPs. The viability of cells irradiated by X-rays exhibited the greatest reduction in the presence of Ag-Ag₂S@BSA-FA NPs in comparison to other counterparts.




Figure 4. (a) Percentage of hemolysis of Ag-Ag₂S@BSA-FA NPs in different concentrations; (b) Cytotoxicity of Ag-Ag₂S@BSA-FA NPs on healthy HFF2 cells; (c) Uptake rate of Ag-Ag₂S@BSA-FA-FITC and Ag-Ag₂S@BSA-FITC NPs by 4T1 cells analyzed by flow cytometry; (d) Cell viability of 4T1 cells under different treatment procedures in the presence and absence of X-ray irradiation (4 Gy) and NPs; (e) 4T1 cells images stained with calcein-AM and PI in the presence and absence of X-ray radiation after different treatments. (Scale bar is 20 µm). Data = mean ± SD; Sign “ns”, **, ***, and **** show no significant difference, and significant difference with $p \leq 0.05$, $p < 0.01$, $p < 0.001$ and $p < 0.0001$, respectively, compared to the control group.

Calcein-AM/PI cell staining assay. Viability staining is an important method for determining cell viability in the context of potential therapeutic applications of prepared NPs. As shown in Fig. 4e, the anticancer activity of Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA under X-ray irradiation were further examined by double-labeling technique using the fluorescent markers Calcein-AM and PI, which stain live and dead cells in green and red, respectively. In Fig. 4e, it is clearly seen that all cells in the control group are alive, there are no dead cells. However, the rate of dead cells gradually increased in Ag-Ag₂S@BSA-FA, Ag-Ag₂S@BSA + X-ray and Ag-Ag₂S@BSA-FA + X-ray groups shown from left to right. Although cell death was observed in all three groups containing silver-based NPs, the Ag-Ag₂S@BSA-FA + X-ray group with appropriate active targeting led to the observation of the highest proportion of dead cells compared to living ones, as the most effective treatment procedure. Intracellular esterases in living cells can convert the virtually nonfluorescent cell-permeable Calcein-AM into the intensely fluorescent calcein. PI enters cells with damaged membranes and enhances fluorescence by binding to DNA, thereby producing a bright red fluorescence in dead cells⁴⁹. Calcein-AM/PI cell staining assay result is well matched with MTT assay result. Under ionizing radiation such as X-Ray, radiosensitizers could enhance the radiosensitivity of cancer cells^{50,51}. Ag NPs demonstrated radio enhancement ability in breast cancer tumor cells⁵². But their ability to efficiently enter and accumulate in tumor cells remains to be improved. It can be improved by active targeting agents. Ag-Ag₂S@BSA-FA + X-ray group showed a higher cell death rate compared to other groups.

Intracellular ROS generation. The DCFH-DA fluorescent probe was used to confirm ROS production within cells. As seen in Fig. 5a, the presence of green color is a criterion of ROS production in the cell. There was no green fluorescence in the control group. However, it was slightly found in the Ag-Ag₂S@BSA-FA and X-ray groups. When cells were treated with Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA under X-ray radiation, the fluorescent intensity increased further, indicating an appropriate production of ROS in these two groups. ROS can




Figure 5. (a) Image of 4T1 cells after incubation with intracellular ROS production detector (DCFH-DA); (b) Clonogenic assay digital images and survival fraction for Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA NPs in the presence and absence of X-ray irradiation. Data = mean ± SD; Sign “ns” *, **, ***, and **** show no significant difference, and significant difference with $p \leq 0.05$, $p < 0.01$, $p < 0.001$ and $p < 0.0001$, respectively, compared to the control group.

damage biomolecules within cells and cause cell death. That's why it has a key role in RT⁵⁰. The Ag-Ag₂S@BSA-FA dramatically induce intracellular ROS overproduction under X-ray radiation.

In vitro colony formation. A clonogenic assay is an *in vitro* assay based on the ability of a single cell to grow into a colony⁵³. The clonogenic assay can be used not only to determine cell death after ionizing radiation therapy (here X-ray), but also to understand the efficacy of other cytotoxic agents. This assay examines the ability of each cell to perform "infinite" division while growing its population. Only a fraction of cells can maintain the colony behavior after implantation in the cell plate. Colony population changes before and after treatment are a criterion for evaluating the test on the cells within 1–3 weeks. In this assay, the cells were stained with crystal violet (0.5%) after implantation, treatment and incubation for one week⁵³. As shown in Fig. 5b, the survival fraction of Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA in the presence of X-ray was halved in comparison to the control group, proving the effectiveness of the successfully designed NPs in radiotherapy treatment. Ag NPs under X-ray irradiation strongly decrease the formation of colonies. The better radiosensitizing activity of Ag-Ag₂S@BSA-FA NPs may be due to their higher intracellular accumulation, since the radiosensitization effects are directly related to the amount of intracellular radiosensitizers⁵⁴.

In vivo assays. *LD₅₀ as an in vivo biosafety indicator.* In addition to determining the toxicity of NPs in *in vitro* studies by HFF2 cells, LD₅₀ testing was carried out after intravenous injection into Balb/C mice. In more detail, four doses of Ag-Ag₂S@BSA-FA NPs (0, 44.44, 66.66 and 100 mg/kg) dispersed in phosphate buffer (PBS) were injected through the tail vein of mice. As shown in Fig. 6a by the Cox regression diagram, no mortality was observed for 30 days.

In vivo radioenhancing ability. The therapeutic effect of radiotherapy was investigated *in vivo* in the presence of Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA NPs. First, 4T1 cancer cells (1×10^6) were injected into the left flank of the mouse to create a tumor. After 12–15 days, when the tumor volume reached 100 mm³, treatment procedure was commenced. As shown in Fig. 6b, the control group along with the X-ray and Ag-Ag₂S@BSA-FA groups had no significant inhibitory effect on tumor growth. However, the inhibitory effect of tumor growth was clearly seen in the groups treated with Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA NPs under X-ray radiation. Notably, in the Ag-Ag₂S@BSA-FA group, the tumor volume reached zero by X-ray. Results also showed that Ag-Ag₂S@BSA-FA NPs had better radiation sensitization than Ag-Ag₂S@BSA NPs, maybe because of greater tumor-homing and specificity of Ag-Ag₂S@BSA-FA NPs. The results showed that the designed NPs play an important role in cancer




Figure 6. (a) Survival of Balb/C mice in LD₅₀ test; (b) Relative tumor volume over the treatment period (21 days); (c) Weight of mice during treatment; (d) Histopathological images of tumors and key organs of mice stained with H&E (scale bar 50 μm).

treatment in animal studies. In addition, as shown in Fig. 6c, there was no discernible pattern in the weight of the mice over the treatment period and the treatment had no negative effects on the weight of the mice.

Histopathology analysis. The key organs and tumors were fixed with 4% paraformaldehyde solution and stained with hematoxylin and eosin (H&E) after removal from the body. As can be seen in Fig. 6d, the H&E staining confirmed that treatment by Ag-Ag₂S@BSA-FA NPs with X-Ray irradiation caused the most damage. As shown in Fig. 6d, the groups treated with the NPs showed no obvious abnormalities. NPs considerably inhibited the growth of tumors under X-ray radiation, without inducing any cytotoxicity on normal tissues. No evident tissue damage could strongly confirm the biocompatibility of the injected NPs³⁵.

Conclusion

In this study, Ag-Ag₂S@BSA-FA NPs with well-defined uniform Janus structures were synthesized using BSA-guided bio-mineralization method. SEM and TEM revealed the presence of homogenous spherical NPs with an average size of ~20 nm. XPS and XRD results showed the coexistence of Ag and Ag₂S nanocrystals in the designed nanoformulation. In addition, the anti-cancer therapeutic effects of the designed NPs in the presence and absence of X-ray radiation were evaluated by a series of in vitro assays on 4T1 cancer cells. The results showed that X-ray irradiation caused more damage to breast cancer cells when applied in combination with radiosensitizer NPs, and this effect was more pronounced in the presence of Ag-Ag₂S@BSA-FA NPs. According to the data we obtained from fluorescent microscopy on cancer cells, it was confirmed that Ag-Ag₂S@BSA and Ag-Ag₂S@BSA-FA produced higher amounts of ROS under X-ray radiation compared to other groups. Finally, similar to in vitro studies, in vivo studies showed that Ag-Ag₂S@BSA-FA performed best in minimizing tumor volume in Balb/C mice, proving the success of proper targeting and radiosensitization.

Data availability

The datasets generated and/or analysed during the current study are not publicly available due to ongoing studies in his line but are available from the corresponding author on reasonable request.

Received: 8 June 2023; Accepted: 16 August 2023

Published online: 13 September 2023

References

1. Ferlay, J. *et al.* Cancer statistics for the year 2020: An overview. *Int. J. Cancer* **149**(4), 778–789 (2021).
2. Kocarnik, J. M. *et al.* Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019. *JAMA Oncol.* **1**, 1 (2021).
3. Sung, H. *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **71**(3), 209–249 (2021).
4. Bilynsky, C., Millot, N. & Papa, A. L. Radiation nanosensitizers in cancer therapy—From preclinical discoveries to the outcomes of early clinical trials. *Bioeng. Transl. Med.* **7**(1), e10256 (2022).
5. Abbas, Z. & Rehman, S. An overview of cancer treatment modalities. *Neoplasms* **1**, 139–157 (2018).
6. Boateng, F. & Ngwa, W. Delivery of nanoparticle-based radiosensitizers for radiotherapy applications. *Int. J. Mol. Sci.* **21**(1), 273 (2019).
7. Talebian, S. *et al.* Facts and figures on materials science and nanotechnology progress and investment. *ACS Nano* **15**(10), 15940–15952 (2021).
8. Mendes, B. B. *et al.* Nanomedicine-based strategies to target and modulate the tumor microenvironment. *Trends Cancer* **7**(9), 847–862 (2021).
9. Lim, E.-K. *et al.* Nanomaterials for theranostics: Recent advances and future challenges. *Nanomater. Neoplasms* **1**, 587–775 (2021).
10. Babaei, M. & Ganjalikhan, M. The potential effectiveness of nanoparticles as radio sensitizers for radiotherapy. *BioImpacts* **4**(1), 15 (2014).
11. Her, S., Jaffray, D. A. & Allen, C. Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements. *Adv. Drug Deliv. Rev.* **109**, 84–101 (2017).
12. Martin, R. F. & Feinendegen, L. E. The quest to exploit the Auger effect in cancer radiotherapy—a reflective review. *Int. J. Radiat. Biol.* **92**(11), 617–632 (2016).
13. Cheng, N. N. *et al.* Chemical enhancement by nanomaterials under X-ray irradiation. *J. Am. Chem. Soc.* **134**(4), 1950–1953 (2012).
14. Pawlik, T. M. & Keyomarsi, K. Role of cell cycle in mediating sensitivity to radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* **59**(4), 928–942 (2004).
15. Kumar, C. G., Poornachandra, Y. & Chandrasekhar, C. Green synthesis of bacterial mediated anti-proliferative gold nanoparticles: inducing mitotic arrest (G2/M phase) and apoptosis (intrinsic pathway). *Nanoscale* **7**(44), 18738–18750 (2015).
16. Mukherjee, S. *et al.* Silver prussian blue analogue nanoparticles: Rationally designed advanced nanomedicine for multifunctional biomedical applications. *ACS Biomater. Sci. Eng.* **6**(1), 690–704 (2019).
17. Haque, S. *et al.* Biosynthesized silver nanoparticles for cancer therapy and in vivo bioimaging. *Cancers* **13**(23), 6114 (2021).
18. Khodke, P. B. *et al.* Silver nanoparticles—A review. *Res. J. Pharm. Technol.* **10**(6), 1820–1833 (2017).
19. Ansari, J. R. *et al.* Enhanced near infrared luminescence in Ag@Ag₂S core-shell nanoparticles. *Appl. Surf. Sci.* **463**, 573–580 (2019).
20. Chen, N. *et al.* BSA capped Au nanoparticle as an efficient sensitizer for glioblastoma tumor radiation therapy. *RSC Adv.* **5**(51), 40514–40520 (2015).
21. Gebregeorgis, A. *et al.* Characterization of silver/bovine serum albumin (Ag/BSA) nanoparticles structure: Morphological, compositional, and interaction studies. *J. Colloid Interface Sci.* **389**(1), 31–41 (2013).
22. Karimi, M. *et al.* Albumin nanostructures as advanced drug delivery systems. *Expert Opin. Drug Deliv.* **13**(11), 1609–1623 (2016).
23. Tai, J.-T. *et al.* Protein–silver nanoparticle interactions to colloidal stability in acidic environments. *Langmuir* **30**(43), 12755–12764 (2014).
24. Zhao, J. *et al.* Increasing the accumulation of aptamer AS1411 and verapamil conjugated silver nanoparticles in tumor cells to enhance the radiosensitivity of glioma. *Nanotechnology* **32**(14), 145102 (2021).
25. Wang, C. *et al.* Recent progress in syntheses and applications of dumbbell-like nanoparticles. *Adv. Mater.* **21**(30), 3045–3052 (2009).
26. Jiang, F. *et al.* One-pot synthesis of large-scaled Janus Ag–Ag₂S nanoparticles and their photocatalytic properties. *CrystEngComm* **13**(24), 7189–7193 (2011).

27. Ghaffarlou, M. *et al.* Bovine serum albumin-mediated synthesis and quorum sensing inhibitory properties of Ag–Ag₂S nanoparticles. *Nanomedicine* **17**(28), 2145–2155 (2022).
28. Nosrati, H. *et al.* Complete ablation of tumors using synchronous chemoradiation with bimetallic theranostic nanoparticles. *Bioact. Mater.* **7**, 74–84 (2022).
29. Nosrati, H. *et al.* Prodrug polymeric nanoconjugates encapsulating gold nanoparticles for enhanced X-Ray radiation therapy in breast cancer. *Adv. Healthcare Mater.* **11**(3), 2102321 (2022).
30. Wang, W. *et al.* Biomimetic mineralization: An opportunity and challenge of nanoparticle drug delivery systems for cancer therapy. *Adv. Healthcare Mater.* **9**(22), 2001117 (2020).
31. Xie, J., Zheng, Y. & Ying, J. Y. Protein-directed synthesis of highly fluorescent gold nanoclusters. *J. Am. Chem. Soc.* **131**(3), 888–889 (2009).
32. Wang, Y. & Yan, X.-P. Fabrication of vascular endothelial growth factor antibody bioconjugated ultrasmall near-infrared fluorescent Ag₂S quantum dots for targeted cancer imaging in vivo. *Chem. Commun.* **49**(32), 3324–3326 (2013).
33. Wang, Y. *et al.* BSA-mediated synthesis of bismuth sulfide nanotheranostic agents for tumor multimodal imaging and thermoradiotherapy. *Adv. Funct. Mater.* **26**(29), 5335–5344 (2016).
34. Birla, S. S. *et al.* Fabrication of silver nanoparticles by *Phoma glomerata* and its combined effect against *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*. *Lett. Appl. Microbiol.* **48**(2), 173–179 (2009).
35. Nosrati, H. *et al.* Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer. *Biomater. Adv.* **140**, 213090 (2022).
36. Shamel, K. *et al.* Green biosynthesis of silver nanoparticles using *Curcuma longa* tuber powder. *Int. J. Nanomed.* **7**, 5603 (2012).
37. Wang, H., Li, G. & Fakhri, A. Fabrication and structural of the Ag₂S–MgO/graphene oxide nanocomposites with high photocatalysis and antimicrobial activities. *J. Photochem. Photobiol. B* **207**, 111882 (2020).
38. Zhao, X. *et al.* Folic acid-conjugated carbon dots as green fluorescent probes based on cellular targeting imaging for recognizing cancer cells. *RSC Adv.* **7**(67), 42159–42167 (2017).
39. Huang, H., *et al.* Reverse screening methods to search for the protein targets of chemopreventive compounds. *Front. Chem.* **138** (2018).
40. Shin, H. S. *et al.* Chemical and size effects of nanocomposites of silver and polyvinyl pyrrolidone determined by X-ray photoemission spectroscopy. *Chem. Phys. Lett.* **383**(3–4), 418–422 (2004).
41. Zhang, P. *et al.* Bimetallic nanoclusters with strong red fluorescence for sensitive detection of hypochlorite in tap water. *Microchim. Acta* **184**(10), 3781–3787 (2017).
42. Kuo, C.-H. & Huang, M. H. Morphologically controlled synthesis of Cu₂O nanocrystals and their properties. *Nano Today* **5**(2), 106–116 (2010).
43. Shan, Z. *et al.* Visible light driven photoelectrochemical properties of Ti@TiO₂ nanowire electrodes sensitized with core–shell Ag@Ag₂S nanoparticles. *J. Phys. Chem. B* **118**(49), 14037–14046 (2014).
44. Diez-Buitrago, B. *et al.* Facile synthesis and characterization of Ag/Ag₂S nanoparticles enzymatically grown in situ and their application to the colorimetric detection of glucose oxidase. *ChemistrySelect* **4**(28), 8212–8219 (2019).
45. Dutta, D. *et al.* Synthesis of Ag–Ag₂S Janus nanoparticles supported on an environmentally benign cellulose template and their catalytic applications. *RSC Adv.* **6**(88), 85173–85181 (2016).
46. ASTM, *Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles*. ASTM International West Conshohocken, PA (2013).
47. Luna-Vázquez-Gómez, R. *et al.* Hemolysis of human erythrocytes by Argovit™ AgNPs from healthy and diabetic donors: An in vitro study. *Materials* **14**(11), 2792 (2021).
48. Shakeri-Zadeh, A. *et al.* Folate receptor-targeted nanoprobe for molecular imaging of cancer: Friend or foe?. *Nano Today* **39**, 101173 (2021).
49. Uchiyama, A. *et al.* Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury. *Hepatology* **48**(5), 1644–1654 (2008).
50. Gao, S., *et al.*, *Nanoparticles Encapsulating Nitrosylated Maytansine to Enhance Radiation Therapy*. *ACS Nano* (2020).
51. Wang, X. *et al.* Enhanced generation of non-oxygen dependent free radicals by Schottky-type heterostructures of Au–Bi₂S₃ nanoparticles via X-ray-induced catalytic reaction for radiosensitization. *ACS Nano* **13**(5), 5947–5958 (2019).
52. Swanner, J. *et al.* Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. *Int. J. Nanomed.* **10**, 3937–3953 (2015).
53. Franken, N. A. P. *et al.* Clonogenic assay of cells in vitro. *Nat. Protoc.* **1**(5), 2315–2319 (2006).
54. Zhao, J. *et al.* Enhancement of radiosensitization by silver nanoparticles functionalized with polyethylene glycol and aptamer As1411 for glioma irradiation therapy. *Int. J. Nanomed.* **14**, 9483–9496 (2019).

Acknowledgements

This work supported by the "Iran National Science Foundation: INSF-98026551", and the "Gorgan university of medical sciences". We gratefully acknowledge the Zanjan University of Medical Science support. Y.N. Ertas acknowledges funding support from the 2232 International Fellowship for Outstanding Researchers Program of TÜBİTAK (Project No: 118C346). MB acknowledges the financial support of the International Atomic Energy Agency (IAEA) under coordinated research project F22070 (IAEA Research Contract No: 23192).

Author contributions

M.G.: investigation, writing—original draft. A.M., N.M., M.S., Y.K., J.C., M.B., Y.N.E. and H.D.: formal analysis, investigation, software, writing—review and editing. H.R., H.N., and S.J.: conceptualization, methodology, writing—review and editing.

Funding

This work supported by the "Iran National Science Foundation: INSF-98026551".

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-40763-9>.

Correspondence and requests for materials should be addressed to H.R., H.N. or S.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023